In the present report, a diagnostic tissue-based test for prostate cancer presence consists of the epigenetic statuses of 3 genes, i.e. GSTP1APC and RASSF1[19], in addition to one control gene, ACTB, used to quantitate amplifiable DNA. Here, RASSF1 is linked to prostate carcinoma.